Imetelstat improves blood transfusion independence in lower-risk myelodysplastic syndromes
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. 2. Grade 3-4 treatment-related adverse events wer...